PULSE BIOSCIENCES, INC. - 8-K Filing
Pulse Biosciences reports interim six-month PRECISE-BTN clinical study results showing 86% of patients achieved primary endpoint of ≥50% nodule volume reduction. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $PLSE